Form 8-K
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): June 11, 2009 (June 9, 2009)
Lifevantage
Corporation
(Exact name of registrant as
specified in its charter)
| |
|
|
|
|
| Colorado |
|
000-30489 |
|
90-0224471 |
| (State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
| |
|
|
11545 W. Bernardo Court,
Suite 301, San Diego, California
|
|
92127 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number,
including area code: (858) 312-8000
| |
| |
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.02 Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On June 11, 2009, Lifevantage
Corporation (the “Company”) announced that the Board of Directors
of the Company has appointed Carrie E. Carlander as Chief Financial Officer of
the Company effective June 9, 2009. The press release announcing the
appointment is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
Ms. Carlander most recently served
as Chief Financial Officer of Genelux Corporation. Prior to Genelux,
Ms. Carlander served as Chief Financial Officer for Adventrx
Pharmaceuticals. She has also served in the role of Vice President Finance for
V-Enable, Inc. and Websense Inc. Ms. Carlander has an MBA in Finance and
Management from San Diego State University, a Bachelor’s Degree from the
University of California at San Diego and is a Certified Management Accountant.
Ms. Carlander will be entitled to an annual base salary of $200,000.
Item 7.01 Regulation FD
Disclosure.
On June 11, 2009, the Company
issued a press release entitled “Carrie Carlander Joins LifeVantage as
Chief Financial Officer.” The press release is attached as
Exhibit 99.1 hereto.
Item 9.01 Financial Statements
and Exhibits.
(d) Exhibits
Exhibit 99.1 Press Release, dated
June 11, 2009, entitled “Carrie Carlander Joins LifeVantage as Chief
Financial Officer.”
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
Date: June 11, 2009
LIFEVANTAGE
CORPORATION
By:
/s/ Bradford K. Amman
Bradford K. Amman
Secretary/Treasurer
3
EXHIBIT INDEX
| |
|
|
| Exhibit No. |
|
Description |
99.1
|
|
Press Release, dated June 11, 2009, entitled “Carrie Carlander Joins LifeVantage as Chief Financial Officer.” |
4
Exhibit 99.1
Exhibit 99.1
|
|
|
FOR IMMEDIATE RELEASE
June 11, 2009
|
|
NEWS
OTCBB: LFVN |
|
|
|
| Contact: |
|
Jan Strode
(619) 890-4040
Jean Golden
(612) 385-2324 |
Carrie Carlander Joins LifeVantage as Chief Financial Officer
SAN DIEGO, CA, June 11, 2009 — LifeVantage Corporation (OTCBB: LFVN), maker of Protandim®, today
announced the Board of Directors has approved the appointment of Carrie Carlander as Chief
Financial Officer.
Ms. Carlander most recently served as Chief Financial Officer of Genelux Corporation. Prior to
Genelux, Ms. Carlander served as Chief Financial Officer for Adventrx Pharmaceuticals. She has also
served in the role of Vice President Finance for V-Enable, Inc. and Websense Inc. Ms. Carlander has
an MBA in Finance and Management from San Diego State University, a Bachelor’s Degree from the
University of California at San Diego and is a Certified Management Accountant.
“I am very pleased that Carrie has joined LifeVantage,” said David W. Brown, President and CEO of
LifeVantage Corporation. “ Her impressive background and track record with dynamic public companies
and her proven abilities in corporate governance, strategic planning, investor relations, and
finance, will be a tremendous asset to LifeVantage.”
“I am excited and honored to join the LifeVantage team, as I feel this is a company with
tremendous growth potential. I look forward to joining David and the rest of the management team
in building upon the great momentum the Company has recently generated through its launch into the
network marketing channel and its rapid attraction of thousands of independent distributors,” said
Ms. Carlander.
-More-
LifeVantage Corporation
LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, natural products
company, dedicated to helping people reach their health and wellness goals through science-based
solutions to oxidative stress. Founded in 2003 and based in San Diego, CA, LifeVantage develops
nutraceutical products, including Protandim®, that leverage the company’s expertise and
that are intended to deliver significant health benefits to consumers. For more information, visit
www.LifeVantage.com.
This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The Company uses the words “anticipate,”
“believe,” “could,” “should,” “estimate,” “expect,” “intend,” “may,” “predict,” “project,” “plan,”
“target” and similar terms and phrases, including references to assumptions, to identify
forward-looking statements. These forward-looking statements are based on the Company’s current
expectations and beliefs concerning future events affecting the Company and involve known and
unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be
materially different from those anticipated and discussed herein. These risks and uncertainties
include, among others, the risk that government regulators and regulations could adversely affect
our business; future laws or regulations may hinder or prohibit the production or sale of our
existing product and any future products; unfavorable publicity could materially hurt our business;
and the Company’s ability to protect our intellectual property rights and the value of our product.
These and other risk factors are discussed in greater detail in the Company’s Annual Report on
Form 10-KSB under the caption “Risk Factors”, and in other documents filed the Company from time to
time with the Securities and Exchange Commission. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this document. All forward-looking
statements are based on information currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these forward-looking statements to reflect
events or circumstances after the date of this document, except as required by law.
###
Note to Editors: Contact Jan Strode at 619-890-4040 or Jean Golden 612-385-2324 for interviews,
photography, and other requests.
